August 11, 2026
The 2026 market has moved decisively from volume toward regeneration: patients increasingly ask for skin quality, not augmentation. Industry commentary this year, including Save Face's 2026 trends review, describes biostimulators such as polynucleotides as the fastest growing part of the injectables market, with exosomes emerging behind them. For injectors the opportunity is real, but so is the responsibility: this category demands more evidence literacy, not less.
The shift from volume to regeneration
The look patients want in 2026 is being described as high fidelity: undetectable, mobile, skin led. That translates clinically into biostimulators, skin boosters and combination protocols (for example microneedling with radiofrequency layered over injectable biostimulation) rather than ever larger filler volumes. If your menu still leads with syringes of volume, demand is quietly moving to clinics that lead with skin health.
Evidence literacy: reading past the marketing
Much of the regenerative evidence base is young: small cohorts, open label designs, manufacturer sponsorship. A 24 week open label study of 15 adults is a promising signal, not proof, and your consultations should reflect that difference. Be precise with patients about what is established (consistent improvements in hydration and elasticity in published polynucleotide studies) versus what is still early, and never let a supplier's slide deck become your consent conversation.
Products, sourcing and due diligence
Before adding any regenerative product, check its regulatory status and classification in your market, the manufacturer evidence, and its safety record. Exosomes deserve particular caution: commentary this year, including from UK register Save Face, stresses being transparent with patients about sourcing and approval status, which varies widely between products and markets. If you cannot explain where a product comes from and what its status is, you are not ready to inject it.
Training, indemnity and the consultation
Complete accredited, hands on training for each new modality and confirm in writing that your malpractice or indemnity policy covers it before your first patient, not after. Then build the consultation around staged, reviewable plans: regenerative treatments suit a course and review structure, which is also honest commercially because results build over months. Photograph consistently, review outcomes, and be willing to tell a patient that the evidence does not yet support what they are asking for.
Common questions
Do I need extra training to offer polynucleotides?
Yes. Treat each regenerative modality as its own competency: complete accredited hands on training, understand the product's protocol and contraindications, and confirm your coverage includes it in writing before treating your first patient.
How should I talk about regenerative evidence with patients?
Distinguish clearly between established findings, such as consistent hydration and elasticity improvements in published polynucleotide studies, and early signals from small or open label trials. Patients consent better, and trust you more, when you are precise about uncertainty.
What should I check before stocking exosome products?
Their regulatory classification and status in your market, the manufacturer's evidence and sourcing transparency, and your coverage position. Industry guidance this year stresses telling patients plainly what a product is and what approval it does and does not have.
Where Sulaia helps
The provider workspace
One calendar, one home, across every clinic you visit.
See how it works